Concepedia

Jasminka Dragovic

JD

Statistics

Publications

16

Citations

831

H-Index

15

Active since

2003

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Scynexis (United States)

Albany Molecular Research (United States)

Jasminka Dragovic is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacology, medicinal chemistry, and drug discovery.

Publications per year

2003–2020

16

Publications

16

The Role of Dipeptidyl Peptidase IV in the Cleavage of Glucagon Family Peptides

Lan Zhu, Constantin Tamvakopoulos, Dan Xie et al. · Journal of Biological Chemistry · 2003 · 221 citations · Full text

, , +17

Discovery of MK-5046, a Potent, Selective Bombesin Receptor Subtype-3 Agonist for the Treatment of Obesity

Iyassu K. Sebhat, Christopher S. Franklin, Michael M.‐C. Lo et al. · ACS Medicinal Chemistry Letters · 2010 · 66 citations · Full text

, , +17

Discovery of MK-7725, A Potent, Selective Bombesin Receptor Subtype-3 Agonist for the Treatment of Obesity

Harry R. Chobanian, Yan Guo, Ping Liu et al. · ACS Medicinal Chemistry Letters · 2012 · 62 citations · Full text

, , +12

Discovery of 4-heteroarylbicyclo[2.2.2]octyltriazoles as potent and selective inhibitors of 11β-HSD1: Novel therapeutic agents for the treatment of metabolic syndrome

Xin Gu, Jasminka Dragovic, Gloria C. Koo et al. · Bioorganic & Medicinal Chemistry Letters · 2005 · 54 citations · Full text

, , +12

Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor

James M. Apgar, Robert R. Wilkening, Dann L. Parker et al. · Bioorganic & Medicinal Chemistry Letters · 2020 · 50 citations

, , +4

1–5 of 16